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Percutaneous Closure versus Medical Therapy for Cryptogenic Stroke in
Patients with a Patent Foramen Ovale: A Meta-Analysis of Randomized
Controlled Trials
Christopher Pickett1, Todd Villines1, Michael Ferguson1, Edward Hulten2
1Walter Reed National Military Medical Center, Bethesda, MD, 2Brigham and
Women's Hospital, Boston, MA
Background: Up to 61% of patients with cryptogenic stroke under the age of 55 years
have been found to have a patent foramen ovale(PFO). Observational studies have
demonstrated reductions in recurrent, neurologic events with PFO closure compared to
medical therapy. Recent randomized controlled trials(RCT) have shown non-signiﬁ-
cant trends toward beneﬁt.
Methods: We systematically searched for RCT of percutaneous PFO closure versus
antiplatelet or anticoagulation medical therapy in patients with cryptogenic stroke or
transient ischemic attack(TIA) and performed a meta-analysis of treatment outcomes.
The primary end point was combined death, stroke, or TIA as deﬁned by each study.
Results: Three RCT of 2303 patients were included. In all, 1150 patients underwent
PFO closure and 1153 received medical therapy and were followed over a median of
2.6(2.0-4.1) years. The pooled incidence of the primary end point was 1.2(95%
conﬁdence interval:0.2–2.3) events/100 patient-years in the PFO closure group and
1.8(0.7–2.9) in the medical therapy group(p¼0.32), with a number needed to
treat(NNT) of 167(100-500). The corresponding pooled hazard ratio(HR) was
0.67(0.44-1.01,p¼0.054) in favor of PFO closure. PFO closure was associated with an
increased incidence of atrial ﬁbrillation, relative risk ¼3.51(1.44-8.55,p¼0.006).
When stratiﬁed by device, the Amplatzer showed a signiﬁcant stroke prevention
beneﬁt, HR¼0.44(0.21-0.95,p¼0.037).
Conclusions: In comparison to medical therapy alone, PFO closure trends toward
decreased hazard of combined events, although the absolute event reduction is small
with a high NNT in the population studied.
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Clopidogrel Pretreatment Effect according to the clinical presentation in Patients
Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
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Jean-Philippe Collet5, Francois Bernasconi6, Gilles Montalescot7
1CH La Fontonne Antibes, Antibes, France, 2Pitié Salpétrière Hospital, Paris, MS,
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France, 6CH La Fontonne Antibes, Antibes, MS, 7N/A, Paris, France
Background: Although Clopidogrel pretreatment is recommended for ACS and stable
coronary patients scheduled for PCI, the beneﬁt of this strategy compared to an
administration at the time of PCI has not been shown on hard clinical outcome. We
performed a systematic review and meta-analysis of all RCTs and registries to eval-
uate the impact of clopidogrel pretreatment on mortality, MACE and major bleeding
after PCI, as compared with no pretreatment.
Methods: We included studies from MEDLINE, EMBASE, CCTR databases that
reported clinical data on mortality and major bleeding. Results were independently
extracted by two observers. A random-effect model was applied. Pretreatment was
deﬁned as the administration of clopidogrel before PCI. Primary efﬁcacy and safety
endpoints were all-cause mortality and major bleeding, respectively. Secondary
endpoints included MACE, MI, Stroke, UVR, Stent Thrombosis (ST), minor and any
bleeding
Results: Of the 392 titles identiﬁed, 15 met the inclusion criteria, published between
Aug-2001 and Sept-2012, including 37 914 patients: 13 628 with stable CAD, 15 650
with NSTE ACS and 8 536 with STEMI. Results for Death, Major Bleeding and
MACE are shown in Figure I.B250 JACC Vol 62/18/Suppl B j October 27–NoConclusions: Among patients scheduled for PCI, clopidogrel pretreatment was not
associated with a lower risk of mortality nor with an increase in major bleeding overall
but with differential effect according clinical presentation. Only STEMI patients
undergoing primary PCI appear to draw a beneﬁt from pre treatment with clopidogrel.
In other patients, treatment at the time of PCI appears to be sufﬁcient.
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Angiographic Success and Procedural Complications in Patients Undergoing
Retrograde Percutaneous Coronary Chronic Total Occlusion Interventions: A
Weighted Meta-Analysis of 3,482 Patients from 26 Studies
Abdallah El Sabbagh1, Vishal G. Patel1, Omar M. Jeroudi1, Tesfaldet T. Michael1,
Mohammed E. Alomar1, Owen Mogabgab1, Eric Fuh1, Michele Roesle2,
Bavana Rangan2, Shuaib Abdullah1, Jeffrey L. Hastings1, Jerrold Grodin1,
Dharam J. Kumbhani1, Dimitrios Alexopoulos3, Panayotis Fasseas4,
Subhash Banerjee1, Emmanouil Brilakis1
1University of Texas Southwestern Medical Center and VA North Texas Healthcare
System, Dallas, TX, 2VA North Texas Healthcare System, Dallas, TX, 3Patras
University Hospital, Patras, Greece, 4Medical College of Wisconsin, Milwaukee, WI
Background: The efﬁcacy and safety proﬁle of retrograde chronic total occlusion
(CTO) percutaneous coronary intervention (PCI) has received limited study. We
sought to perform a weighted meta-analysis of the complication risk during retrograde
CTO PCI.
Methods: We conducted a meta-analysis of 26 studies published between 2006 and
April 2013 reporting in-hospital outcomes of retrograde CTO PCI. Data on procedural
success, frequency of death, emergent coronary artery bypass graft surgery (CABG),
stroke, myocardial infarction (MI), perforation, tamponade, stent thrombosis, major
vascular or bleeding events, contrast nephropathy, and radiation skin injury were
collected.
Results: A total of 26 studies with 3,482 patients and 3,493 target CTO lesions were
included. Primary retrograde CTO PCI was attempted in 52.4% and 42% of the
patients had a prior failed antegrade attempt. The CTO target vessel was the right
coronary artery (62%), left anterior descending artery (25%), circumﬂex (11.4%), or
other vessel (1.6%). Pooled estimates of outcomes are shown in the Table.
Conclusions: Retrograde CTO PCI is associated with high procedural success rate
and acceptable risk for procedural complications.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
